摘要
罗替戈汀为选择性多巴胺D1/D2/D3受体激动剂,其透皮贴剂是第一个非麦角类多巴胺受体激动剂贴剂。罗替戈汀贴剂24h有效,能对帕金森病人持续提供多巴胺能刺激,目前获得FDA和EMA批准上市。对罗替戈汀贴剂研究情况进行简要综述。
Rotigotine transdermal patch is the first transdermal non-ergot dopamine agonist, which is a selective dopamine D1/D2/D3 receptor agonist. Rotigotine patch is effective over 24 h providing a continuous dopaminergic stimulation in patients with Parkinson＇s disease （PD） and is approved for use in treatment of PD by the FDA and EMA. This paper is a review of current status of Rotigotine transdermal patch.
出处
《药物评价研究》
CAS
2012年第1期67-70,共4页
Drug Evaluation Research
关键词
罗替戈汀
透皮贴剂
帕金森病
药理
药代
临床
结晶
Rotigotine
transdermal patch
Parkinson＇s disease （PD）
pharmacology
pharmacokinetics
clinic
crystallization
